These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 14525705

  • 1. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E, Cantón R, Pascual A, Tubau F, Morosini MI, Almaraz F, Perea E, Martín R, Jones RN, Baquero F.
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K, Akasaka T, Sato K.
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [Abstract] [Full Text] [Related]

  • 3. Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001).
    Jones RN, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):273-8. PubMed ID: 12729999
    [Abstract] [Full Text] [Related]

  • 4. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN, Pfaller MA, SENTRY Antimicrobial Surveillance Program Participants Group (USA).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [Abstract] [Full Text] [Related]

  • 5. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens.
    Noviello S, Ianniello F, Leone S, Esposito S.
    J Antimicrob Chemother; 2003 Nov; 52(5):869-72. PubMed ID: 14519672
    [Abstract] [Full Text] [Related]

  • 6. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
    Jones RN, Fritsche TR, Sader HS, Stilwell MG.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH.
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
    Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe).
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068
    [Abstract] [Full Text] [Related]

  • 11. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.
    Christiansen KJ, Bell JM, Turnidge JD, Jones RN.
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2049-55. PubMed ID: 15155198
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):27-32. PubMed ID: 17383140
    [Abstract] [Full Text] [Related]

  • 14. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [Abstract] [Full Text] [Related]

  • 15. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K, Watabe E, Yoshimori K, Shikano M, Sato Y, Hasegawa M, Kobayashi I.
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of fluoroquinolones against common respiratory pathogens.
    Aydemir S, Tunger A, Cilli F.
    West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM, Mazzucco CE, Lawrence LE, Ho H, Warr G, Barrett JF, Frosco M.
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [Abstract] [Full Text] [Related]

  • 18. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 19. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
    Fung-Tomc J, Gradelski E, Huczko E, Minassian B, Bonner DP.
    Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.